Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | CH5132799 |
Trade Name | |
Synonyms | MEN1611|CH 5132799|CH-5132799|PA 799|PA799 |
Drug Descriptions |
MEN1611 (CH5132799) inhibits class I PI3Ks, including the PIKC3A mutants E542K, E545K, and H1047R, resulting in decreased PI3K pathway signaling and decreased tumor growth (PMID: 21558396). |
DrugClasses | PI3K Inhibitor (Pan) 40 |
CAS Registry Number | 1007207-67-1 |
NCIT ID | C158603 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cetuximab + CH5132799 | CH5132799 Cetuximab | 0 | 1 |
CH5132799 | CH5132799 | 14 | 0 |
CH5132799 + Everolimus | CH5132799 Everolimus | 0 | 0 |
CH5132799 + Fulvestrant + Trastuzumab | CH5132799 Fulvestrant Trastuzumab | 0 | 1 |
CH5132799 + Trastuzumab | CH5132799 Trastuzumab | 0 | 1 |